Cell therapy and bispecific antibody administration in community oncology: a case study–based implementation roadmap
NCODA Oncology and Hematology Meeting Abstracts · 07.04.2026
DOI: 10.67209/hbqi1345 ↗Kurz gefasst
Fachartikel in der Zeitschrift NCODA Oncology and Hematology Meeting Abstracts, online erschienen am 07.04.2026. Verfasst von K Patel und 19 weiteren Autor:innen. Die Arbeit nennt 28 Literaturangaben.
Abstract (Originalsprache)
Background
Bispecific antibodies have transformed cancer therapy but remain largely inaccessible in community oncology due to cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) concerns requiring hospitalization and intensivemonitoring.
Objectives
Evaluate the impact of prophylactic tocilizumab on the incidence of CRS and ICANS during outpatient administration of bispecific antibodies in community oncology settings. Implement a structured outpatient workflow for safe community-based delivery of bispecific antibodies that reduces hospitalization and treatment burden while maintaining clinical efficacy.
Methods
We implemented prophylactic tocilizumab administration prior to bispecific antibody infusion at a community oncology practice across follicular lymphoma, small cell lung cancer, and multiple myeloma patients receiving epcoritamab-bysp, mosunetuzumab-axgb, tarlatamab-dlle, and teclistamab.
Results
No high-grade CRS or ICANS events occurred. All treatments were delivered entirely in outpatient community settings without hospitalization. Patients achieved responses consistent with pivotal trial data while experiencing substantially reduced treatment burden compared to traditional protocols.
Conclusions
Prophylactic tocilizumab enables safe community-based bispecific antibody delivery. This case study-based analysis provides a detailed implementation roadmap for community practices to expand therapeutic capabilities while advancing health equity. Funding: Not applicable.
Zitieren
APA
Patel, K., Boccia, R., Olson, N., Nadkarni, R., Naidu, D., Kodali, A., Clinton, N., Lozano, R., Anandpura, N., Naidu, S., Nathwani, N., Gor, A., Rabara, V., Ramaswamy, S., Willey, J., Carrasco, S., Clinton, N., Britton, S., Rabara, R., & Niar, S. (2026). Cell therapy and bispecific antibody administration in community oncology: a case study–based implementation roadmap. NCODA Oncology and Hematology Meeting Abstracts. https://doi.org/10.67209/hbqi1345
Vancouver
Patel K, Boccia R, Olson N, Nadkarni R, Naidu D, Kodali A, et al. Cell therapy and bispecific antibody administration in community oncology: a case study–based implementation roadmap. NCODA Oncology and Hematology Meeting Abstracts. 2026. doi:10.67209/hbqi1345
BibTeX
@article{Patel2026,
author = {Patel, K and Boccia, R and Olson, N and Nadkarni, R and Naidu, D and Kodali, A and Clinton, N and Lozano, R and Anandpura, N and Naidu, S and Nathwani, N and Gor, A and Rabara, V and Ramaswamy, S and Willey, J and Carrasco, S and Clinton, N and Britton, S and Rabara, R and Niar, S},
title = {Cell therapy and bispecific antibody administration in community oncology: a case study–based implementation roadmap},
journal = {NCODA Oncology and Hematology Meeting Abstracts},
year = {2026},
doi = {10.67209/hbqi1345}
}
EUVIMED